In creating inter partes reexamination, Congress hoped to provide a faster, cheaper alternative for resolving questions of patent validity in the U.S. Patent & Trademark Office (USPTO) rather than in the courts. As a measure of the procedure’s growing popularity and availability, the rate of requests for inter partes reexamination has steadily increased each year, totaling over 308 since the procedure was created in November 1999. But, while the pace of reexam requests continues to increase, the end results of completed proceedings have received relatively little attention.
Read the complete article by clicking on the link below.
Author(s)
Related Insights
April 14, 2026
Health Care Law Today
FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products
On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
April 14, 2026
Foley Career Perspectives
Trust Your Instincts: Susan Pravda on Leadership, Relationships, and Resilience
Foley partner Susan Pravda is a business lawyer focused on mergers and acquisitions, venture capital, initial public offerings, and related securities transactions and is head of Foley’s Health Care & Life Sciences Sector. She also serves as the firm’s chief strategic talent acquisition partner.
April 14, 2026
Blogs
When to Litigate and When to Walk Away
Clients faced with defending or initiating litigation often begin with the question: “Can we win?” The question sounds simple enough, and if the law is favorable, the instinctive answer might be “yes.” But “winning” in court doesn’t happen, and can’t be evaluated, in a vacuum. In reality, the odds of success in litigation depend not only on the law and facts of the case but also on any business constraints and potential consequences.